[go: up one dir, main page]

MX9206844A - Compuestos, composiciones y metodos para unir substancias de influencia biologica a membranas de superficie de bioparticulas - Google Patents

Compuestos, composiciones y metodos para unir substancias de influencia biologica a membranas de superficie de bioparticulas

Info

Publication number
MX9206844A
MX9206844A MX9206844A MX9206844A MX9206844A MX 9206844 A MX9206844 A MX 9206844A MX 9206844 A MX9206844 A MX 9206844A MX 9206844 A MX9206844 A MX 9206844A MX 9206844 A MX9206844 A MX 9206844A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
methods
surface membranes
biological influence
Prior art date
Application number
MX9206844A
Other languages
English (en)
Inventor
Gregory A Kopia
Paul K Horan
Brian D Gray
David E Troutner
Katharine A Muirhead
Kamleshkumar A Sheth
Chia-En Lin
Yu Susan Z Zhizhou
Lever Kwamena E Baidoo Slezak
Original Assignee
Zynaxis Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/884,432 external-priority patent/US5667764A/en
Application filed by Zynaxis Technologies Inc filed Critical Zynaxis Technologies Inc
Publication of MX9206844A publication Critical patent/MX9206844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan compuestos que tienen la capacidad de unir substancias terapéuticamente activas a partículas bio-compatible que contienen lípidos, tales como células o virus. Estos compuestos incluyen una porción de influencia biológica, que comprende una substancia terapéuticamente activa, la cual está enlazada a través de porción de enlazamiento a cuando menos un substituyente hidrocarburo, seleccionado de manera que el compuesto sea lo suficientemente no polar, para impartir una capacidad de unión del lípido al compuesto.
MX9206844A 1991-11-27 1992-11-27 Compuestos, composiciones y metodos para unir substancias de influencia biologica a membranas de superficie de bioparticulas MX9206844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79893691A 1991-11-27 1991-11-27
US07/884,432 US5667764A (en) 1988-05-02 1992-05-15 Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles

Publications (1)

Publication Number Publication Date
MX9206844A true MX9206844A (es) 1993-07-01

Family

ID=27122052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9206844A MX9206844A (es) 1991-11-27 1992-11-27 Compuestos, composiciones y metodos para unir substancias de influencia biologica a membranas de superficie de bioparticulas

Country Status (10)

Country Link
EP (1) EP0643706A1 (es)
JP (2) JP3682974B2 (es)
CN (1) CN1074911A (es)
AU (2) AU3221993A (es)
CA (1) CA2124329C (es)
IL (1) IL103874A0 (es)
MX (1) MX9206844A (es)
NZ (1) NZ245271A (es)
PH (1) PH31676A (es)
WO (1) WO1993011120A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339975T1 (de) † 1993-07-19 2006-10-15 Angiotech Pharm Inc Anti-angiogener stent und verfahren zu dessen herstellung
ES2210258T5 (es) 1993-07-29 2009-01-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Procedimiento de tratamiento de la ateroesclerosis o reestenosis usando un agente estabilizante de microtubulos.
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6004536A (en) * 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
WO1997024459A1 (en) * 1995-12-29 1997-07-10 Phanos Technologoes, Inc. Method for reducing unwanted cellular adhesions
US5871436A (en) * 1996-07-19 1999-02-16 Advanced Cardiovascular Systems, Inc. Radiation therapy method and device
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO1998043618A2 (en) * 1997-03-31 1998-10-08 Neorx Corporation Use of cytoskeletal inhibitors for the prevention of restenosis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7045305B1 (en) * 1998-04-08 2006-05-16 The Regents Of The University Of California Methods and reagents for targeting organic compounds to selected cellular locations
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
NZ517188A (en) * 1999-08-23 2003-11-28 Angiogene Inc Radioactively coated device and method of making same for preventing restenosis
CO5261573A1 (es) 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
IT1319168B1 (it) * 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.
IL155107A0 (en) 2000-10-16 2003-10-31 Conor Medsystems Inc Expandable medical device for delivery of beneficial agent
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US7776529B2 (en) 2003-12-05 2010-08-17 Life Technologies Corporation Methine-substituted cyanine dye compounds
KR20070091609A (ko) 2004-11-22 2007-09-11 지이 헬스케어 에이에스 세포외 기질을 표적화하기 위한 조영제
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1885718B1 (en) 2005-05-11 2017-03-15 Life Technologies Corporation Fluorescent chemical compounds having high selectivity for double stranded dna, and methods for their use
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
TWI637992B (zh) * 2013-11-26 2018-10-11 住友化學股份有限公司 Rubber composition and vulcanization aid
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US10975060B2 (en) 2016-11-28 2021-04-13 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
EP3883613A1 (en) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
JP7423888B2 (ja) * 2019-11-22 2024-01-30 株式会社同仁化学研究所 脂質二分子膜染色用色素及びそれを用いた脂質二分子膜の染色方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE3170134D1 (en) * 1980-09-02 1985-05-30 Fuji Photo Film Co Ltd Method for immunochemical measurement
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US4762701A (en) * 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4906749A (en) * 1987-06-30 1990-03-06 Viomedics Inc. Cyclic anhydride derivatives of chromophors
EP0396626A1 (en) * 1988-01-19 1990-11-14 Board Of Regents, The University Of Texas System Glycosides, liposomal compositions thereof, and methods for their use
JP3038339B2 (ja) * 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting

Also Published As

Publication number Publication date
CA2124329A1 (en) 1993-06-10
JPH08502719A (ja) 1996-03-26
JP4095847B2 (ja) 2008-06-04
WO1993011120A1 (en) 1993-06-10
AU1991497A (en) 1997-07-10
CN1074911A (zh) 1993-08-04
CA2124329C (en) 2008-11-18
JP3682974B2 (ja) 2005-08-17
EP0643706A4 (en) 1994-12-27
AU3221993A (en) 1993-06-28
JP2003026657A (ja) 2003-01-29
IL103874A0 (en) 1993-04-04
PH31676A (en) 1999-01-18
NZ245271A (en) 1996-03-26
EP0643706A1 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
MX9206844A (es) Compuestos, composiciones y metodos para unir substancias de influencia biologica a membranas de superficie de bioparticulas
Pickett et al. Initiation of phospholipase A2 activity in human platelets by the calcium ion ionophore A23187
EA200201042A1 (ru) Способ лечения с использованием конъюгатов лиганд-иммуноген
MX168497B (es) Ultrafiltracion de flujo tangencial por afinidad
AR061222A1 (es) Derivados de 2-oxo-piridina, 2-oxo-quinolina y 2-oxo-isoquinolina, composiciones farmaceuticas que los comprenden y el uso de los mismos en medicamentos para tratar enfermedades mediadas por la scd.
DE69832375D1 (de) Verwendungsmethoden von makrozyklischen laktonen als mittel zur umkehrung der mehrfach-medikamentresistenz in krebs- und anderen zellen
EA200500300A1 (ru) Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение
JP2000297046A5 (ja) 感染予防治療剤、抗エンドトキシン剤、ワクチンアジュバント剤および成長促進剤
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
ES2071995T3 (es) Composicion para la activacion de macrofagia.
LeJohn et al. Cytokinins regulate calcium binding to a glycoprotein from fungal cells
EP0271521A1 (en) Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
Bertini et al. A novel type of granules observed in toad endothelial cells and their relationship with blood pressure active factors
ES548492A0 (es) Procedimiento para la preparacion de substancias secas obte-nibles por liofilizacion
Camussi et al. Porins and lipopolysaccharide stimulate platelet activating factor synthesis by human mesangial cells
Isogai et al. Role of platelet-activating-factor (PAF) on cellular responses after stimulation with leptospire lipopolysaccharide
Nakada et al. Susceptibility of lipids to mercurials
Brom et al. Effect of sodium fluoride on the generation of lipoxygenase products from human polymorphonuclear granulocytes, mononuclear cells and platelets--indication for the involvement of G proteins
AR007020A1 (es) Tratamiento de asma con tnfr-ig
FR2573077B1 (fr) Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores
DE69929189T2 (de) Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche
Krüger et al. Carcinogenic action of dimethylnitrosamine in trout not related to methylation of nucleic acids and protein in vivo
SE9702698D0 (sv) Compositions for lubricating and separating tissues and biological membranes
Saito et al. Inhibitory effect of Toxoplasma lysate antigen on the multiplication of transplanted tumor in mice